The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma

Non-alcoholic fatty liver disease (NAFLD) is the fastest growing cause of hepatocellular carcinoma (HCC) worldwide (1). It is anticipated that the burden of NAFLD-related HCC will continue to increase in tandem with the global obesity epidemic (2,3). This has become a global issue of concern, as liver cancer is associated with significant morbidity and mortality, and is currently the third leading cause of cancer death (4).

In this review, Geh et al. provided a comprehensive overview of NAFLD-related HCC and its diagnosis, treatment and surveillance (5). The authors described the distinct clinical characteristics of NAFLD-HCC patients, as well as the impact of specific treatments on NAFLD-HCC patients. They described how patients with NAFLD-HCC tend to be older, with greater likelihood of having obesity, type 2 diabetes mellitus (DM), cardiovascular disease, and cerebrovascular disease, and lower likelihood of having cirrhosis. These are in line with a recent systematic review and meta-analysis of 61 studies (94,636 patients) which corroborated these findings, and determined that NAFLD-HCC patients were more likely to have uninodular lesions and larger tumour diameters (6). However, this meta-analysis did not find a difference in Barcelona clinic liver cancer (BCLC) stage and overall survival between NAFLD-HCC and non-NAFLD HCC patients, although there were a limited number of included studies that described the comparative survival between etiologies of liver disease (6).

As NAFLD-related HCC patients are generally older with more comorbidities, this may affect fitness for surgery and influence peri-operative outcomes. Geh and colleagues described how the data for short-term outcomes in NAFLD-related HCC patients who undergo surgical resection are variable, and NAFLD-HCC patients who undergo liver transplantation were found to be at increased risk of short-term complications. In contrast, long-term outcomes were comparable to those with HCC of other etiologies. A recent large meta-analysis determined that 1-year overall survival after surgical resection for HCC in general is high at 90%, although 5-year survival is substantially poorer at 55%, but there were limited data for NAFLD-related HCC (7). Another meta-analysis determined that surgical resection was associated with lower overall survival compared to liver transplantation, likely because liver transplant treats both the tumour and the surrounding cirrhotic micro-environment, but survival was similar between HCC patients with uninodular lesions who underwent surgical resection and liver transplantation (8,9). Patient selection, pre-operative planning and attention to peri-operative care are key to achieving good short and long-term surgical outcomes, and are even more important in the setting of NAFLD-related HCC where patients are more likely to be overweight or obese with multiple cardiovascular comorbidities (5,10,11).

A multi-pronged strategy is required to improve outcomes for patients with NAFLD-related HCC. There is an urgent need to improve HCC surveillance in NAFLD individuals. Currently, as Geh and colleagues have highlighted, surveillance in NAFLD individuals is suboptimal—only 33% of NAFLD-HCC patients had HCC surveillance prior to diagnosis of HCC (6). There is no consensus on the best strategy for surveillance in NAFLD patients without cirrhosis. Geh and colleagues discuss how it is not cost-effective to conduct routine surveillance for all patients with NAFLD without cirrhosis, although some major society guidelines recommend HCC surveillance for NAFLD patients with cirrhosis or advanced fibrosis with ultrasound (US) with or without alpha-fetoprotein every 6 months (12). Further research needs to be done to develop risk models or risk scores to identify NAFLD patients at high risk of developing HCC for enrolment into surveillance programmes (13). In addition, limited visualization on US is associated with decreased sensitivity and higher likelihood of false negatives in HCC surveillance (14). Obesity, which is common among NAFLD individuals, is a well-known risk factor for limited visualization on US (15). A possible alternative imaging modality for HCC surveillance is abbreviated magnetic resonance imaging (aMRI), which has been shown in a recent prospective study to be superior to US for visualization in patients with NAFLD cirrhosis, especially those who are obese (16). More studies are required to evaluate the benefit of alternative imaging such as aMRI when US is deemed inadequate.

NAFLD-related HCC is now a global public health challenge. Understanding the unique characteristics and challenges of managing patients with NAFLD-related HCC are essential to the development of better strategies for early detection and treatment.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-362/coif). DQH has served as an advisory board member for Eisai. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Huang DQ, Singal AG, Kono Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 2022;34:969-977.e2. [Crossref] [PubMed]
2. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18:223-38. [Crossref] [PubMed]
3. Tan DJH, Setiawan VW, Ng CH, et al. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. Hepatology 2022; Epub ahead of print. [Crossref] [PubMed]
4. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. [Crossref] [PubMed]
5. Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [Crossref] [PubMed]
6. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol 2022;23:521-30. [Crossref] [PubMed]
7. Reveron-Thornton RF, Teng MLP, Lee EY, et al. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022;6:1813-26. [Crossref] [PubMed]
8. Koh JH, Tan DJH, Ong Y, et al. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr 2022;11:78-93. [Crossref] [PubMed]
9. Huang DQ, Muthiah MD, Zhou L, et al. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cell Mol Gastroenterol Hepatol 2021;11:1313-25. [Crossref] [PubMed]
10. Campani C, Bensi C, Milani S, et al. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [Crossref] [PubMed]
11. Tan DJH, Lim WH, Yong JN, et al. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clin Gastroenterol Hepatol 2022; Epub ahead of print. [Crossref] [PubMed]
12. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80. [Crossref] [PubMed]
13. Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology 2022; Epub ahead of print. [Crossref] [PubMed]
14. Chong N, Schoenberger H, Yekkaluri S, et al. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther 2022;55:683-90. [Crossref] [PubMed]
15. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77. [Crossref] [PubMed]
16. Huang DQ, Fowler KJ, Liau J, et al. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 2022;55:820-7. [Crossref] [PubMed]